Nathalie Dompé is an Italian business leader and the CEO of Dompé farmaceutici. The company makes medicines and has deep roots in Milan. She also leads Dompé Holdings and is married to Silicon Valley investor Chamath Palihapitiya.
She did not begin her career as a drug company chief. Nathalie studied business, explored theater, worked on social projects, and helped bring the family’s medicines into the United States. In 2026, she took on a larger role in a company that now reaches patients around the world.
Here, we will look at Nathalie’s family roots, studies, career growth, work with new drugs and AI, and life with her husband and children. We will also cover her age, business roles, and the milestones that shaped her path.
Quick Bio: Nathalie Dompé
- Name: Nathalie Dompé
- Nationality: Italian
- Age: 39 in October 2026
- Current work: CEO of Dompé farmaceutici and Dompé Holdings
- Education: Business Administration, Bocconi University in Milan
- Father: Sergio Dompé
- Husband: Chamath Palihapitiya
- Marriage: 2023
- Children: Two children with Chamath
- Other roles: Board roles at Philogen and Movendo; former president of Teatro Stabile d’Abruzzo
The Dompé Family Business in Milan
The Dompé story began in Milan in the late 1800s, long before its current work with biotech. The family’s early pharmacy business grew into a maker of medicines and then a global drug company.
Nathalie belongs to the fifth generation linked to that business.
Her father, Sergio Dompé, helped move the group toward modern biotech and the study of rare diseases. He remains listed as executive president, while Nathalie now holds the CEO role.
That gives the business a clear shift from one generation of leaders to the next.
The family’s long history shows how much the drug industry has changed. What began as a local pharmacy now needs skilled teams, research labs, and offices in many countries.
Nathalie grew up close to that world, but she did not plan from childhood to run the company. In an interview in October 2026, she recalled visiting its Milan offices with her father when she was young.
Her path to the top developed over time.
Nathalie Dompé’s Education and Early Interests
Nathalie Dompé earned a Business Administration degree from Bocconi University in Milan, graduating with honors. Bocconi gave her a base in the money, people, and plans behind a large business.
Yet business was not her first choice of subject.
She has said that she once wanted to study medicine. After her degree, she went to London to learn about theater at Central Saint Martins.
She also spent time on the runway, including fashion work for Armani.
Her time in theater soon became part of her public work. A few years later, she took charge of a theater group in Abruzzo while building her career at Dompé.
At 11, Nathalie was badly hurt in a ski accident and spent a long time in recovery. She later spoke about how that hard period shaped her sense of self.
Early Work in Science Education and the Arts
Corporate Social Responsibility at Dompé
Her early job at Dompé was in corporate social responsibility, a part of the business that deals with its duties to people and communities. By 2012, she was leading that work for the group.
It gave her a different starting point from the drug labs and sales teams.
In 2012, she helped introduce GENIale, a science program involving more than 600 students in the L’Aquila area. It gave young people a way to explore biotech and meet the ideas behind modern drugs.
A later project, GENEration Biotechnology, brought lessons about modern science into local middle schools. Students could use online tools to explore the field and learn how it affects daily life.
Leading an Arts Institution in Abruzzo
In October 2015, Nathalie Dompé became president of Teatro Stabile d’Abruzzo, a theater group in Italy’s Abruzzo region. The role fit her past studies in theater as well as her interest in how large groups are run.
The theater was working to change how it managed funds and reached its audience. During her term, the organization discussed new forms of support, changes to its rules, and ways to manage its work more smoothly.
She left the presidency in December 2017 as her duties at Dompé grew. The two-year term gave her experience in running an arts group before she took on more work in the drug industry.
How Nathalie Dompé Built Her Pharmaceutical Career
The Move to the United States
As the family company expanded, She turned more of her work toward the American market. She moved to the United States in 2018.
That year, Dompé gained approval to sell a new eye treatment to patients there.
The drug was Oxervate, also called cenegermin, used to treat a rare eye disease known as neurotrophic keratitis. The U.S. Food and Drug Administration approved it in August 2018.
That gave Dompé a major route into a large new market.
The illness can harm the clear front surface of the eye, which can lead to serious sight problems. Bringing a drug like this to market needs far more than a scientific result.
A company must plan how doctors learn about it, how patients can get it, and how it will reach hospitals and clinics.
Nathalie Dompé worked on that broader market effort. Her work focused on growth, drug launches, and ties with other firms.
Lab teams did the science behind the medicine.
From Co-CEO to CEO in 2026
For several years, she was known as co-CEO of Dompé farmaceutici. In 2026, Nathalie became CEO, taking over the lead role from her father as the company entered its next phase.
Sergio continues as executive president.
Her CEO role at Dompé farmaceutici covers key plans for drug launches in the United States, market growth, and ties with leaders in drug research and technology. She also serves as CEO of the wider family holding company.
The two posts have different aims. Dompé farmaceutici develops and sells medicines.
Dompé Holdings has interests in several fields, including drugs, farming, and technology. Nathalie must look at both the drug business and the wider group.
What the Company Makes and Why It Matters
Dompé is not a small local pharmacy today. It researches, makes, and sells medicines, with work across Europe and the United States.
It focuses on areas such as eye disease, pain, and conditions affecting the brain.
The company reports about €1.7 billion in sales for 2025 and around 1,100 staff worldwide. Those figures show the size of the group she leads, not her own pay.
One notable part of its work is nerve growth factor, or NGF. This is a protein that plays a role in the health of nerve cells.
Dompé’s work with this science helped lead to its eye treatment, Oxervate.
Rare drugs can be costly to develop because trials and safety checks take time, even when few people have the illness. Oxervate’s U.S. launch marked a major new stage for the Milan company.
Nathalie Dompé’s Plans for AI Drug Discovery
Nathalie Dompé also spends time with leaders in the tech world. One area she now speaks about often is artificial intelligence in drug discovery.
She wants tools that can help drug teams test new ideas more quickly.
Dompé uses a platform called Exscalate to screen huge sets of possible drug molecules on computers. That lets teams narrow down which ideas might be worth testing in a lab.
It does not mean a computer can skip human trials or prove that a drug is safe on its own.
In October 2026, she discussed plans to improve Exscalate’s ability to predict drug safety and toxicity. She also spoke about the need to guard private health data while using AI.
This is where her work in Silicon Valley links back to the drug company in Milan. Tech firms may bring computing tools, while drug teams bring medical questions and safety needs.
Nathalie’s role includes helping those groups work together.
She has also pointed to gaps in how women’s health is studied. Better data and more focused research may lead to better care, but any new ideas must still pass the same tests for safety and benefit as other medical treatments.
Board Roles and Recognition Beyond the CEO Title
Her business work extends beyond Dompé. Nathalie sits on the boards of firms including Philogen, which works in biotech, and Movendo Technology, which develops tools for physical recovery and movement.
Board members help oversee a firm’s direction rather than doing its daily lab work.
In September 2022, Nathalie accepted a Women Corporate Directors Visionary Award in New York on behalf of Dompé farmaceutici. The award honored the company’s leadership and governance as a private business.
It was not a personal award for inventing a drug.
The event brought the family group into a room with other major firms. It was part of Nathalie’s growing role on the world stage.
Chamath Palihapitiya, Marriage, and Family Life
Nathalie’s husband is Chamath Palihapitiya, the investor known for his years at Facebook and for founding Social Capital. He is also a host of the All-In podcast.
Their marriage has made Nathalie more familiar to people who follow Silicon Valley news.
The couple married in 2023 in Portofino, Italy. Nathalie has spoken about how they met through social ties involving Chelsea Clinton and her husband, Marc Mezvinsky, when she was seeking business links in California.
Her life now spans the United States and Italy. She has a home life in California while keeping close ties to the family company in Milan.
In her own account, work calls across the time difference are a normal part of her week.
Nathalie and Chamath have two children together. He also has three children from his earlier marriage to Brigette Lau.
Nathalie has spoken about the joys and demands of a home with five children in the wider family.
Her children are not part of her professional work, and family stories do not need to expose their private routines. What is clear is that she balances the needs of an international business with her role as a mother.
Nathalie Dompé’s Age and Personal Finances
Nathalie Dompé was described as 39 years old in October 2026. That gives readers a current age, though a precise birth date has not been part of the main company biography.
Her current role is tied to the company’s growth in the United States and its new technology projects.
Her personal net worth is a separate issue from the size of the company. Dompé’s sales are the money the business brings in, not the amount Nathalie owns.
Her husband’s investments also do not provide a figure for her own assets.
Nathalie Dompé leads both a drug company and its family holding group. Her work now links business plans in Milan with new medicines and partners in California.
Questions Readers Ask About Nathalie Dompé
Who Is Nathalie Dompé?
She is an Italian pharmaceutical executive and the CEO of Dompé farmaceutici and Dompé Holdings. She is also part of the family that has led the business for generations.
How Old Is Nathalie Dompé?
She was 39 in October 2026. Her exact birthday is not given in the company’s main executive biography.
Who Is Nathalie Dompé’s Husband?
She is married to Chamath Palihapitiya, a venture investor and former Facebook executive. They married in 2023 in Portofino, Italy.
Does Nathalie Dompé Have Children?
Yes. She and Chamath have two children together.
He has three older children from an earlier marriage.
Where Did Nathalie Dompé Study?
She graduated with honors in Business Administration from Bocconi University in Milan. She also studied theater in London.
Is Nathalie Dompé a Doctor?
She is a business leader, not a doctor. Her university degree is in business, and her role in the drug industry focuses on strategy, growth, and the work needed to bring medicines to market.
What Is Nathalie Dompé’s Net Worth?
There is no clear public figure for her personal net worth. The company’s sales and the wealth of her husband or father cannot be used as a total for her own finances.
A Career That Connects Italy and Silicon Valley
Nathalie’s path runs from a family business in Milan to theater work, social projects, and the U.S. drug market. She now leads a company with a long history while looking at how new tools might change its work.
By 2026, Nathalie Dompé has moved from school science projects to guiding drug launches and global growth. Her next challenge is to bring newer computing tools into a field where safety, sound science, and patient needs still come first.
You may also read: David Rooklin: Ilana Glazer’s Husband, Scientist and Biotech Founder.



